---
title: Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial
  Infarction
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38587254/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240408180508&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with acute myocardial infarction, multivessel
  coronary artery disease, and additional cardiovascular risk factors, four weekly
  infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke,
  or death from cardiovascular causes than placebo through 90 days. (Funded by CSL
  Behring; AEGIS-II ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, ...